Sensei biotherapeutics to present preclinical data on sns-103 at the cri-enci eighth international immunotherapy conference

Boston, sept. 04, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on sns-103 will be presented in a poster session at the cri-enci eighth international immunotherapy conference, being held september 8-11, 2024, at the gaylord national resort & convention center in national harbor, md.
CRI Ratings Summary
CRI Quant Ranking